GLP-1 Receptor Agonists: Clinical Evidence and Weight Loss Benefits
GLP-1 receptor agonist weight loss clinical evidence shows these medications effectively reduce appetite and improve metabolic health. Clinical trials demonstrate significant weight loss with agents like semaglutide and tirzepatide. Understanding weight…
GLP-1 Rebound Weight Gain: Clinical Evidence and Management
GLP-1 rebound effects cause weight regain after stopping therapy, reflecting metabolic setpoint return. Understanding these effects is crucial for managing long-term weight. This article reviews clinical evidence and management approaches for GLP-1…
GLP-1 Receptor Agonists: Clinical Evidence and FAQs
Appetite regulation mechanisms are central to the effectiveness of GLP-1 receptor agonists in weight management. These medications work by slowing gastric emptying and increasing satiety signals. Understanding these mechanisms helps clinicians optimize…
GLP-1 Receptor Agonist Clinical Evidence: FDA Warns Telehealth
Telehealth regulatory compliance is critical for prescribers of GLP-1 receptor agonists amid FDA warnings. The FDA targets misleading marketing claims about compounded GLP-1 products. Providers must ensure patient safety by distinguishing FDA-approved…
Munchies Phenomenon: WSU Study Explores Cannabis Benefits and Hunger
New research shows how THC triggers appetite brain mechanisms to stimulate hunger even when the body isn't hungry. This discovery helps patients with chronic illness manage appetite loss. Understanding THC triggers appetite brain pathways improves…
Cannabis: What Is the Profile of Adults at Low Risk of Dependence?
A University of Montreal study highlights the cannabis low risk use profile among adults, showing 63% at low risk for cannabis use disorder. Lower-risk users tend to consume cannabis occasionally and socially. Understanding this profile helps inform harm…